Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility$350 million initial term loan funded at close and up to an additional $150 million available ...

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...

Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical ...

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain my Hold rating on MDGL stock.

Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL), currently trading near $300 with analysts seeing up to 80% upside potential according to InvestingPro data, will present a comparative meta ...

QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund ...

On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic dysfunction-associated steatohepatitis/MASH in Europe.

What will Boston Pharmaceuticals CEO Sophie Kornowski do now that the company is selling off its pipeline and winding down operations? Whatever it is, data will take her there.